Volume 32, Issue 7 (October 2021)                   Stud Med Sci 2021, 32(7): 478-489 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Moazzami Goudarzi M, Fazeli M R, Akhavan sepahi A, Eidi A. ASSESSMENT OF ANTIVIRAL ACTIVITY OF LACTOBACILLUS RHAMNOSUS AGAINST HERPES SIMPLEX VIRUS TYPE II. Stud Med Sci. 2021; 32 (7) :478-489
URL: http://umj.umsu.ac.ir/article-1-5562-en.html
Tehran University of Medical Sciences , mofazeli@yahoo.com
Abstract:   (413 Views)
Background & Aims: High prevalence of urogenital infections among women and the increasing emergence of drug-resistant organisms are a challenging topic. Due to this background, it is reasonable to consider probiotics for combating the urogenital infections. This study is an attempt to evaluate the effect of Lactobacillus rhamnosus against Herpes Simplex Virus Type II.
Materials & Methods: Within donated lactobacilli, biochemical and molecular characterization was carried out to find Lactobacillus rhamnosus isolates. Then to evaluate how cell-free supernatant (CFS) of Lactobacillus rhamnosus may affect the pathogenesis of herpes simplex virus type II, a plaque formation counting test was done on HeLa Cells by plaque-forming assay.
Results: The supernatant of Lactobacillus rhamnosus culture significantly reduced plaque formation by herpes simplex virus II and almost the same results were obtained for standard strain. The inhibitory effects of the two supernatants were independent of H202 or H+ secretion by candidate lactobacilli, but the result was more reasonable for wild type in comparison to the standard strain of lactobacillus rhamnosus.
Conclusion: Considering the most effective inhibitory results (6h before virus contamination) and also by probable in vivo generalization of result, it is more possible to consider vaginal microbiome as an inhibitor for initial steps of viral attachment. Otherwise, when HeLa cells were successfully contaminated by HSV II, the inhibitory result of lactobacilli was reduced. A variety of mechanisms may be responsible for interruption in viral-host cell interaction, virus neutralization, and post-infected intracellular viral procedures.
Full-Text [PDF 562 kb]   (130 Downloads)    
Type of Study: Research | Subject: میکروبیولوژی

References
1. 1-Nam H, Whang K, Lee Y. Analysis of vaginal lactic acid producing bacteria in healthy women. J Microbiol 2007; 45(6): 515-20. [Article] [PubMed]
2. 2-Abdolalipour E, Mahooti M, Salehzadeh A, Torabi A, Mohebbi SR, Gorji A, et al. Evaluation of the antitumor immune responses of probiotic Bifidobacterium bifidum in human papillomavirus-induced tumor model. Microb Pathog 2020;145: 104207.
3. 3-Pabich WL, Fihn SD, Stamm WE, Scholes D, Boyko EJ, Gupta K. Prevalence and determinants of vaginal flora alterations in postmenopausal women. J Infect Dis 2003; 188: 1054-8.
4. 4-Li Y, Yu T, Yan H, Li D, Yu T, Yuan T, et al. Vaginal microbiota and HPV infection: Novel mechanistic insights and therapeutic strategies. Infect Drug Resist 2020; 13: 1213–20.
5. 5-Palma E, Recine N, Domenici L, Giorgini M, Pierangeli A, Panici PB. Long-term Lactobacillus rhamnosus BMX 54 application to restore a balanced vaginal ecosystem: A promising solution against HPV-infection. BMC Infect Dis 2018; 18: 13.
6. 6- Sewankambo N, Gray RH, Wawer MJ, Paxton L, McNaim D, Wabwire-Mangen F. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet 1997; 350(9077): 546-50.
7. 7- Tamrakar R, Yamada T, Furuta I, Cho K, Morikawa M, Yamada H, et al. Association between Lactobacillus species and bacterial vaginosis-related bacteria, and bacterial vaginosis scores in pregnant Japanese women. BMC Infect Dis 2007; 7: 128.
8. 8-Oo KM, Ayelwin A, Kyaw YY, Tun WM, Fukada K, Goshima A, et al. Safety and long-term effect of the probiotic FK-23 in patients with hepatitis C virus infection. Biosci Microbiota Food Health.2016; 35: 2015–24.
9. 9- Klebanoff SJ, Coombs RW. Viricidal effect of Lactobacillus acidophilus on human immunodeficiency virus type 1: possible role in heterosexual transmission. J Exp Med 1991; 174:289–92.
10. 10-Haghighat L, Crum-Cianflone NF. The potential risks of probiotics among HIV-infected persons: Bacteraemia due to Lactobacillus acidophilus and review of the literature. Int J STD AIDS 2016;27(13):1223-30.
11. 11- D’Angelo C, Reale M, Costantini E. Microbiota and probiotics in health and HIV infection. Nutrients 2017; 6: 615.
12. 12 -Zuckerman RA, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, Zuniga R, et al. Herpes simplex virus (HSV) suppression with Val acyclovir reduces rectal and blood plasmaHIV-1 levels in HIV- 1/HSV-2-seropositive men: a randomized, doubleblind, placebo-controlled crossover trial. J Infect Dis 2007; 196(10): 1500-8.
13. 13- McGroarty JA. Probiotic use of lactobacilli in the human female urogenital tract. FEMS Immunol Med Microbiol 1993; 6(4): 251-64.
14. 14- Zabihollahi R, Motevaseli E, Sadat SM, Azizi-Saraji AR, Asaadi Dalaie S, Modarressi MH. Inhibition of HIV and HSV infection by vaginal lactobacilli in vitro and in vivo. Daru 2012; 9:48-53.
15. 15- Sha BE, Zariffard MR, Wang QJ, Chen HY, Bremer J, Cohen MH, et al. Female genital-tract HIV load correlates inversely with Lactobacillus species but positively with bacterial vaginosis and Mycoplasma hominis. J Infect Dis 2005; 191:25–32.
16. 16- Bayané A, Roblain D, Dubois-Dauphin R, Destain J. Assessment of the physiological and biochemical characterization of a Lactic acid bacterium isolated from chicken faeces in sahelian region. Afr J Biotechnol 2006; 5: 629-34.
17. 17-Ou YC, Fu HC, Tseng CW, Wu CH, Tsai CC, Lin H. The influence of probiotics on genital high-risk human papilloma virus clearance and quality of cervical smear: A randomized placebo-controlled trial. BMC Womens Health2019; 19: 103.
18. 18- Ehrstrom S, Daroczy K, Rylander E, Samuelsson C, Johannesson U. Lactic acid bacteria colonization and clinical outcome after probiotic supplementation in conventionally treated bacterial vaginosis and vulvovaginal candidiasis. Microbes Infect 2010;12: 691–9.
19. 19-Nagot N, Ouedraogo A, Defer MC, Vallo R, Mayaud P, Van de Perre P. Association between bacterial vaginosis and Herpes simplex virus type-2 infection: implications for HIV acquisition studies. Sex Transm Infect 2007; 83(5): 365-8.
20. 20- Reikvam DH, Meyer-Myklestad MH, Trøseid M, Stiksrud B. Probiotics to manage inflammation in HIV infection. Curr Opin Infect Dis 2020;33(1):34-43.
21. 21- Conti C, Malacrino C, Mastromarino P. Inhibition of herpes simplex virus type 2 by vaginal lactobacilli. J Physiol Pharmacol 2009; 60: 19-26.
22. 22-Cherpes TL, Meyn LA, Krohn MA, Hillier SL. Risk factors for infection with herpes simplex virus type 2: role of smoking, douching, uncircumcised males, and vaginal flora. Sex Transm Dis 2003; 30: 405-10.
23. 23-Ouwehand A, Salminen S, Isolauri E. Probiotics: an overview of benefical effects. Antonie Van Leeuwenhoek 2002;82(1-4):279-89.
24. 24- Pizarro-Cerdá J, Cossart P. Bacterial adhesion and entry into host cells. Cell 2006; 124:715-27.
25. 25- Chen X, Xu J, Shuai J, Chen J, Zhang Z, Fang W. The S-layer proteins of Lactobacillus crispatus strain ZJ001 is responsible for competitive exclusion against Escherichia coli O157:H7 and Salmonella typhimurium. Int J Food Microbiol 2007; 115:307-12.
26. 26- Khani S, Motamedifar M, Golmoghaddam H, Hosseini HM, Hashemizadeh Z. In vitro study of the effect of a probiotic bacterium Lactobacillus rhamnosus against herpes simplex virus type 1. Braz J Infect Dis 2012;16(2):129-35.
27. 27- Antushevich H. Interplays between inflammasomes and viruses, bacteria (pathogenic and probiotic), yeasts and parasites. Immunol Lett 2020; 228: 1–14.
28. 28- Majamaa, H, Isolauri E, Saxelin M, Vesikari T. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J. Pediat. Gastroenterol Nutr 1995; 20: 333–83.
29. 29- Verhoeven V, Renard N, Makar A, Royen PV, Bogers JP, Lardon F, et al. Probiotics enhance the clearance of human papillomavirus-related cervical lesions: A prospective controlled pilot study. Eur J Cancer Prev 2013; 22: 46–51.
30. 30- Hummelen R, Changalucha J, Butamanya NL, Cook A, Habbema JDF, Reid G. Lactobacillus rhamnosus GR-1 and L.euteri RC-14 to prevent or cure bacterial vaginosis among women with HIV. Int J Gynecol Obstet 2010; 111: 245–8.
31. 31- Reikvam DH, Meyer-Myklestad MH, Trøseid M, Stiksrud B. Probiotics to manage inflammation in HIV infection. Curr Opin Infect Dis 2020;33(1):34-43.
32. 32- Scheri GC, Fard SN, Schietroma I, Mastrangelo A, Pinacchio C, Giustini N, et al. Modulation of tryptophan/serotonin pathway by probiotic supplementation in human immunodeficiency virus-positive patients: Preliminary results of a new study approach. Int J Trytophan Res 2017; 10: 1178646917710668.
33. 33- Freedman SB, Xie J, Nettel-Aguirre A, Pang XL, Chui L, Williamson-Urquhart S, et al. A randomized trial evaluating virus-specific effects of a combination probiotic in children with acute gastroenteritis. Nat Commun 2020;11(1):2533.

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.